Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis characterized by skin and mucosal fragility due to mutations in the *COL7A1* gene \[[@CR1]\]. No curative treatment is available \[[@CR2]\]. It has been shown that the level of activation of dermal metalloproteinases (MMP) could modulate the phenotype in RDEB patients \[[@CR3]--[@CR5]\] and that epigallocatechin-3-gallate (EGCG), a green tea extract \[[@CR6]--[@CR8]\], is able to regulate this activity *in vitro and ex vivo* \[[@CR9]\].

We then evaluated the efficacy of oral EGCG to improve skin impairment in RDEB patients in a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial. The trial was approved by the local ethics committee and was registered in the Clinical Trial Register (NCT00951964). Patients of both sexes, over 2 years of age, with generalized severe or intermediate RDEB, confirmed by immunohistological analysis of skin biopsy, were recruited. Patients received treatment or placebo for 4 months, followed by a 2-month wash-out period and then by the other treatment for 4 months (Fig. [1](#Fig1){ref-type="fig"}). Dosage of EGCG treatment depended on the patient's weight (from 400 to 800 mg a day) (Additional file [1](#MOESM1){ref-type="media"}, Supplementary Methods).Fig. 1Study design. Each patient has a 4 month period of treatment separated by a 2 month period of wash-out

The main outcome was binary: *success*, defined as a decrease ≥ 20 % in the number of new blisters per day counted by patients at each dressing, upon 7 consecutive dressings before the initial and final visit of each treatment period, or *failure* of treatment. Secondary outcomes were the affected cutaneous surface area, the severity of mucosal impairment, skin fragility, itch and the mean duration of healing measured on 3 new blisters selected by patients in the first week of each period of treatment (Additional file [2](#MOESM2){ref-type="media"}: Table S1). Adverse events were collected by investigators at each visit. Assuming an expected success rate of 30 % in the EGCG group and 5 % in the placebo group, with 80 % power and 5 % type I error, we planned to include 22 patients. The main outcome was analysed in a modified intention to treat (mITT) and *per protocol*, secondary outcomes in a mITT.

Findings {#Sec1}
========

Seventeen patients were included in this study, mean age 19.4 years (±16.2 SD). One patient did not start treatment and was not included in the mITT population (*n* = 16). Only 10/16 patients were included in the *per protocol* analysis (available data for each visit in both treatment periods for the main outcome). Eight patients/16 (50 %) had a decrease of at least 20 % in the mean number of new blisters per day with EGCG and 5/16 (31 %) with placebo in the mITT analysis. This difference was not statistically significant (Prescott's test, *p* = 0.78). Results were similar in *per protocol* analysis (*p* = 1). Analyses of secondary outcomes showed no difference between the 2 treatment periods (Table [1](#Tab1){ref-type="table"}) despite a dramatic reduction of the mean duration of wound in the EGCG group (-14.62 days ± 18.76) compared to the placebo group (1.78 ± 14.65). Tolerance was good with 26 and 16 adverse events in the EGCG and placebo group respectively (*p* = 0.47) (Additional file [3](#MOESM3){ref-type="media"}: Table S2).Table 1Statistical analysis of secondary outcomesEvolution of score (end of the period - beginning of the period)Polyphenon E® Mean ± SD (*N*)Placebo Mean ± SD (*N*)*p* valueSurface area- 4.07 ± 7.62 (12)- 4.42 ± 9.84 (14)0.93Skin fragility- 0.90 ± 2.46 (12)- 0.64 ± 2.06 (14)0.75Mucosal involvement0.55 ± 1.12 (8)1.97 ± 1.64 (6)0.07Itch- 1.17 ± 3.53 (12)0 ± 2.16 (14)0.38Mean duration of wound healing (days)-14.62 ± 18.76 (7)1.78 ± 14.65 (9)0.21*N* number of patients, *SD* standard deviation

Generalized DEB is a rare and severe genodermatosis. Hence, evaluation of a new treatment in a controlled randomized and double-blind trial is challenging. In this study, even if fewer new blisters per day were observed in the EGCG arm as compared with the placebo and the mean duration of wound healing was shorter, we failed to show a statistically significant difference. These disappointing results can be explained by several limitations of our study. First, under-enrolment and the high rate of missing data for the main outcome are of important concern. Low enrolment is a major drawback for studies on all rare and severe diseases \[[@CR10]--[@CR13]\]. Indeed, despite the active involvement of the DEBRA France patients' support group and the main French centres for EB care, together with the reimbursement of the patient's travel expenses, only 17 patients instead of the 22 planned could be enrolled and only 10 completed the study. Shorter studies with less visits and/or home evaluation by a study nurse and/or international studies could improve the patient recruitment and protocol adherence. Moreover, factors influencing the severity of phenotype in DEB are complex and not only related to the MMP activity as recently shown \[[@CR3], [@CR14], [@CR15]\]. Finally the high rate of therapeutic success in the placebo group is intriguing, but seems to be frequent in the few controlled versus placebo published studies on DEB \[[@CR10]--[@CR13]\]. The variable course of DEB, depending on numerous factors such as the weather, associated diseases and or/secondary complications or trauma, is well known. We tried to minimize the impact of these factors by counting the number of new blisters per day averaged on seven consecutive dressings before each visit. However other outcome measures like a validated EB severity score may be more relevant. Analysis of the inclusion date of each patient did not support an influence of seasonal variation. EGCG is a potentially interesting and safe treatment for DEB patients. An international randomized, double-blinded and placebo-controlled trial with targeted subpopulation is necessary.
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